Top

Published in:

Open Access 01-12-2017 | Topic Review

Current trends in mouse models of glioblastoma

Authors: Masafumi Miyai, Hiroyuki Tomita, Akio Soeda, Hirohito Yano, Toru Iwama, Akira Hara

Published in: Journal of Neuro-Oncology | Issue 3/2017

Abstract

Glioblastoma is the most deadly brain tumor type and is characterized by a severe and high rate of angiogenesis, remaining an incurable disease in the majority of cases. Mechanistic understanding of glioblastoma initiation and progression is complicated by the complexity of genetic and/or environmental initiating events and lack of clarity regarding the cell or tissue of origin. To determine these mechanisms, mouse models that recapitulate the molecular and histological characteristics of glioblastoma are required. Unlike in other malignancies, viral-mediated mouse models of glioblastoma rather than chemically induced mouse models have been developed because of its sensitivity to viruses. Based on recent molecular analyses reported for human glioblastoma, this review critically evaluates genetically engineered, xenograft, allograft, viral-mediated, and chemically induced mouse models of glioblastoma. Further, we focus on the clinical value of these models by examining their contributions to studies of glioblastoma prevention, tumorigenesis, and chemoresistance.

Committee of Brain Tumor Registry of Japan: Report of Brain Tumor Registry of Japan (2001–2004). Neurol Med Chir (Tokyo) : 1-102, 2014. Neurol Med Chir (Tokyo) 13 (1):12

Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, European Organisation for R, Treatment of Cancer Brain T., Radiotherapy G, National Cancer Institute of Canada Clinical Trials G (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352 (10):987–996. doi:10.1056/NEJMoa043330 CrossRefPubMed

Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW (2016) The 2016 World Health Organization Classification of tumors of the central nervous system: a summary. Acta Neuropathol 131(6):803–820. doi:10.1007/s00401-016-1545-1 CrossRefPubMed

Ohgaki H, Kleihues P (2013) The definition of primary and secondary glioblastoma. Clin Cancer Res 19(4):764–772. doi:10.1158/1078-0432.CCR-12-3002 CrossRefPubMed

Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, Zheng S, Chakravarty D, Sanborn JZ, Berman SH, Beroukhim R, Bernard B, Wu CJ, Genovese G, Shmulevich I, Barnholtz-Sloan J, Zou L, Vegesna R, Shukla SA, Ciriello G, Yung WK, Zhang W, Sougnez C, Mikkelsen T, Aldape K, Bigner DD, Van Meir EG, Prados M, Sloan A, Black KL, Eschbacher J, Finocchiaro G, Friedman W, Andrews DW, Guha A, Iacocca M, O’Neill BP, Foltz G, Myers J, Weisenberger DJ, Penny R, Kucherlapati R, Perou CM, Hayes DN, Gibbs R, Marra M, Mills GB, Lander E, Spellman P, Wilson R, Sander C, Weinstein J, Meyerson M, Gabriel S, Laird PW, Haussler D, Getz G, Chin L, Network TR (2013) The somatic genomic landscape of glioblastoma. Cell 155(2):462–477. doi:10.1016/j.cell.2013.09.034 CrossRefPubMedPubMedCentral

Cancer Genome Atlas Research N (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455 (7216):1061–1068. doi:10.1038/nature07385 CrossRef

Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A, Hahn WC, Ligon KL, Louis DN, Brennan C, Chin L, DePinho RA, Cavenee WK (2007) Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 21(21):2683–2710. doi:10.1101/gad.1596707 CrossRefPubMed

Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, Olivi A, McLendon R, Rasheed BA, Keir S, Nikolskaya T, Nikolsky Y, Busam DA, Tekleab H, Diaz LA Jr, Hartigan J, Smith DR, Strausberg RL, Marie SK, Shinjo SM, Yan H, Riggins GJ, Bigner DD, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321(5897):1807–1812. doi:10.1126/science.1164382 CrossRefPubMedPubMedCentral

Weissenberger J, Steinbach JP, Malin G, Spada S, Rulicke T, Aguzzi A (1997) Development and malignant progression of astrocytomas in GFAP-v-src transgenic mice. Oncogene 14(17):2005–2013. doi:10.1038/sj.onc.1201168 CrossRefPubMed

10.

Ding H, Roncari L, Shannon P, Wu X, Lau N, Karaskova J, Gutmann DH, Squire JA, Nagy A, Guha A (2001) Astrocyte-specific expression of activated p21-ras results in malignant astrocytoma formation in a transgenic mouse model of human gliomas. Cancer Res 61(9):3826–3836PubMed

11.

Ding H, Shannon P, Lau N, Wu X, Roncari L, Baldwin RL, Takebayashi H, Nagy A, Gutmann DH, Guha A (2003) Oligodendrogliomas result from the expression of an activated mutant epidermal growth factor receptor in a RAS transgenic mouse astrocytoma model. Cancer Res 63(5):1106–1113PubMed

12.

Holland EC (2001) Gliomagenesis: genetic alterations and mouse models. Nat Rev Genet 2(2):120–129. doi:10.1038/35052535 CrossRefPubMed

13.

Zhu Y, Guignard F, Zhao D, Liu L, Burns DK, Mason RP, Messing A, Parada LF (2005) Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma. Cancer Cell 8(2):119–130. doi:10.1016/j.ccr.2005.07.004 CrossRefPubMedPubMedCentral

14.

Weiss WA, Burns MJ, Hackett C, Aldape K, Hill JR, Kuriyama H, Kuriyama N, Milshteyn N, Roberts T, Wendland MF, DePinho R, Israel MA (2003) Genetic determinants of malignancy in a mouse model for oligodendroglioma. Cancer Res 63(7):1589–1595PubMed

15.

Bardella C, Al-Dalahmah O, Krell D, Brazauskas P, Al-Qahtani K, Tomkova M, Adam J, Serres S, Lockstone H, Freeman-Mills L, Pfeffer I, Sibson N, Goldin R, Schuster-Boeckler B, Pollard PJ, Soga T, McCullagh JS, Schofield CJ, Mulholland P, Ansorge O, Kriaucionis S, Ratcliffe PJ, Szele FG, Tomlinson I (2016) Expression of Idh1R132H in the murine subventricular zone stem cell niche recapitulates features of early gliomagenesis. Cancer Cell 30(4):578–594. doi:10.1016/j.ccell.2016.08.017 CrossRefPubMedPubMedCentral

16.

von Jonquieres G, Mersmann N, Klugmann CB, Harasta AE, Lutz B, Teahan O, Housley GD, Frohlich D, Kramer-Albers EM, Klugmann M (2013) Glial promoter selectivity following AAV-delivery to the immature brain. PLoS ONE 8(6):e65646. doi:10.1371/journal.pone.0065646 CrossRef

17.

Holland EC, Celestino J, Dai C, Schaefer L, Sawaya RE, Fuller GN (2000) Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice. Nat Genet 25(1):55–57. doi:10.1038/75596 CrossRefPubMed

18.

Uhrbom L, Dai C, Celestino JC, Rosenblum MK, Fuller GN, Holland EC (2002) Ink4a-Arf loss cooperates with KRas activation in astrocytes and neural progenitors to generate glioblastomas of various morphologies depending on activated Akt. Cancer Res 62(19):5551–5558PubMed

19.

Hambardzumyan D, Amankulor NM, Helmy KY, Becher OJ, Holland EC (2009) Modeling adult gliomas using RCAS/t-va technology. Trans Oncol 2(2):89-IN86. doi:10.1593/tlo.09100 CrossRef

20.

Dai C, Celestino JC, Okada Y, Louis DN, Fuller GN, Holland EC (2001) PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo. Genes Dev 15(15):1913–1925. doi:10.1101/gad.903001 CrossRefPubMedPubMedCentral

21.

Wei Q, Clarke L, Scheidenhelm DK, Qian B, Tong A, Sabha N, Karim Z, Bock NA, Reti R, Swoboda R, Purev E, Lavoie JF, Bajenaru ML, Shannon P, Herlyn D, Kaplan D, Henkelman RM, Gutmann DH, Guha A (2006) High-grade glioma formation results from postnatal pten loss or mutant epidermal growth factor receptor expression in a transgenic mouse glioma model. Cancer Res 66(15):7429–7437. doi:10.1158/0008-5472.CAN-06-0712 CrossRefPubMed

22.

Ikawa M, Tanaka N, Kao WWY, Verma IM (2003) Generation of transgenic mice using lentiviral vectors: a novel preclinical assessment of lentiviral vectors for gene therapy. Mol Ther 8(4):666–673. doi:10.1016/s1525-0016(03)00240-5 CrossRefPubMed

23.

Marumoto T, Tashiro A, Friedmann-Morvinski D, Scadeng M, Soda Y, Gage FH, Verma IM (2009) Development of a novel mouse glioma model using lentiviral vectors. Nat Med 15(1):110–116. doi:10.1038/nm.1863 CrossRefPubMedPubMedCentral

24.

Alcantara Llaguno S, Chen J, Kwon CH, Jackson EL, Li Y, Burns DK, Alvarez-Buylla A, Parada LF (2009) Malignant astrocytomas originate from neural stem/progenitor cells in a somatic tumor suppressor mouse model. Cancer Cell 15(1):45–56. doi:10.1016/j.ccr.2008.12.006 CrossRefPubMedPubMedCentral

25.

Misuraca KL, Hu G, Barton KL, Chung A, Becher OJ (2016) A novel mouse model of diffuse intrinsic pontine glioma initiated in Pax3-expressing cells. Neoplasia 18(1):60–70. doi:10.1016/j.neo.2015.12.002 CrossRefPubMedPubMedCentral

26.

Misuraca KL, Barton KL, Chung A, Diaz AK, Conway SJ, Corcoran DL, Baker SJ, Becher OJ (2014) Pax3 expression enhances PDGF-B-induced brainstem gliomagenesis and characterizes a subset of brainstem glioma. Acta Neuropathol Commun 2:134. doi:10.1186/s40478-014-0134-6 CrossRefPubMedPubMedCentral

27.

Engebraaten O, Hjortland GO, Hirschberg H, Fodstad O (1999) Growth of precultured human glioma specimens in nude rat brain. J Neurosurg 90(1):125–132. doi:10.3171/jns.1999.90.1.0125 CrossRefPubMed

28.

Mahesparan R, Read TA, Lund-Johansen M, Skaftnesmo KO, Bjerkvig R, Engebraaten O (2003) Expression of extracellular matrix components in a highly infiltrative in vivo glioma model. Acta Neuropathol 105(1):49–57. doi:10.1007/s00401-002-0610-0 PubMed

29.

Antunes L, Angioi-Duprez KS, Bracard SR, Klein-Monhoven NA, Le Faou AE, Duprez AM, Plenat FM (2000) Analysis of tissue chimerism in nude mouse brain and abdominal xenograft models of human glioblastoma multiforme: what does it tell us about the models and about glioblastoma biology and therapy? J Histochem Cytochem 48(6):847–858. doi:10.1177/002215540004800613 CrossRefPubMed

30.

Taillandier L, Antunes L, Angioi-Duprez KS (2003) Models for neuro-oncological preclinical studies: solid orthotopic and heterotopic grafts of human gliomas into nude mice. J Neurosci Methods 125(1–2):147–157. doi:10.1016/s0165-0270(03)00043-8 CrossRefPubMed

31.

Shu Q, Wong KK, Su JM, Adesina AM, Yu LT, Tsang YT, Antalffy BC, Baxter P, Perlaky L, Yang J, Dauser RC, Chintagumpala M, Blaney SM, Lau CC, Li XN (2008) Direct orthotopic transplantation of fresh surgical specimen preserves CD133 + tumor cells in clinically relevant mouse models of medulloblastoma and glioma. Stem Cells 26(6):1414–1424. doi:10.1634/stemcells.2007-1009 CrossRefPubMed

32.

Suggitt M, Bibby MC (2005) 50 years of preclinical anticancer drug screening: empirical to target-driven approaches. Clin Cancer Res 11(3):971–981PubMed

33.

Tateishi K, Wakimoto H, Iafrate AJ, Tanaka S, Loebel F, Lelic N, Wiederschain D, Bedel O, Deng G, Zhang B, He T, Shi X, Gerszten RE, Zhang Y, Yeh JR, Curry WT, Zhao D, Sundaram S, Nigim F, Koerner MV, Ho Q, Fisher DE, Roider EM, Kemeny LV, Samuels Y, Flaherty KT, Batchelor TT, Chi AS, Cahill DP (2015) Extreme vulnerability of IDH1 mutant cancers to NAD + depletion. Cancer Cell 28(6):773–784. doi:10.1016/j.ccell.2015.11.006 CrossRefPubMedPubMedCentral

34.

Ashizawa T, Miyata H, Iizuka A, Komiyama M, Oshita C, Kume A, Nogami M, Yagoto M, Ito I, Oishi T, Watanabe R, Mitsuya K, Matsuno K, Furuya T, Okawara T, Otsuka M, Ogo N, Asai A, Nakasu Y, Yamaguchi K, Akiyama Y (2013) Effect of the STAT3 inhibitor STX-0119 on the proliferation of cancer stem-like cells derived from recurrent glioblastoma. Int J Oncol 43(1):219–227. doi:10.3892/ijo.2013.1916 CrossRefPubMed

35.

Plowman J, Waud WR, Koutsoukos AD, Rubinstein LV, Moore TD, Grever MR (1994) Preclinical antitumor activity of temozolomide in mice: efficacy against human brain tumor xenografts and synergism with 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Res 54(14):3793–3799PubMed

36.

Singh D, Chan JM, Zoppoli P, Niola F, Sullivan R, Castano A, Liu EM, Reichel J, Porrati P, Pellegatta S, Qiu K, Gao Z, Ceccarelli M, Riccardi R, Brat DJ, Guha A, Aldape K, Golfinos JG, Zagzag D, Mikkelsen T, Finocchiaro G, Lasorella A, Rabadan R, Iavarone A (2012) Transforming fusions of FGFR and TACC genes in human glioblastoma. Science 337(6099):1231–1235. doi:10.1126/science.1220834 CrossRefPubMedPubMedCentral

37.

Wykosky J, Hu J, Gomez GG, Taylor T, Villa GR, Pizzo D, VandenBerg SR, Thorne AH, Chen CC, Mischel PS, Gonias SL, Cavenee WK, Furnari FB (2015) A urokinase receptor-Bim signaling axis emerges during EGFR inhibitor resistance in mutant EGFR glioblastoma. Cancer Res 75(2):394–404. doi:10.1158/0008-5472.CAN-14-2004 CrossRefPubMed

38.

Mercurio L, Ajmone-Cat MA, Cecchetti S, Ricci A, Bozzuto G, Molinari A, Manni I, Pollo B, Scala S, Carpinelli G, Minghetti L (2016) Targeting CXCR4 by a selective peptide antagonist modulates tumor microenvironment and microglia reactivity in a human glioblastoma model. J Exp Clin Cancer Res 35:55. doi:10.1186/s13046-016-0326-y CrossRefPubMedPubMedCentral

39.

Szabo E, Schneider H, Seystahl K, Rushing EJ, Herting F, Weidner KM, Weller M (2016) Autocrine VEGFR1 and VEGFR2 signaling promotes survival in human glioblastoma models in vitro and in vivo. Neuro Oncol 18(9):1242–1252. doi:10.1093/neuonc/now043 CrossRefPubMedPubMedCentral

40.

Kessler JD, Kahle KT, Sun T, Meerbrey KL, Schlabach MR, Schmitt EM, Skinner SO, Xu Q, Li MZ, Hartman ZC, Rao M, Yu P, Dominguez-Vidana R, Liang AC, Solimini NL, Bernardi RJ, Yu B, Hsu T, Golding I, Luo J, Osborne CK, Creighton CJ, Hilsenbeck SG, Schiff R, Shaw CA, Elledge SJ, Westbrook TF (2012) A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis. Science 335(6066):348–353. doi:10.1126/science.1212728 CrossRefPubMed

41.

Sharpe MA, Livingston AD, Gist TL, Ghosh P, Han J, Baskin DS (2015) Successful treatment of intracranial glioblastoma xenografts with a monoamine oxidase B-activated pro-drug. EBioMedicine 2(9):1122–1132. doi:10.1016/j.ebiom.2015.08.013 CrossRefPubMedPubMedCentral

42.

Joo KM, Kim J, Jin J, Kim M, Seol HJ, Muradov J, Yang H, Choi YL, Park WY, Kong DS, Lee JI, Ko YH, Woo HG, Lee J, Kim S, Nam DH (2013) Patient-specific orthotopic glioblastoma xenograft models recapitulate the histopathology and biology of human glioblastomas in situ. Cell Rep 3(1):260–273. doi:10.1016/j.celrep.2012.12.013 CrossRefPubMed

43.

Wainwright DA, Horbinski CM, Hashizume R, James CD (2017) Therapeutic hypothesis testing with rodent brain tumor models. Neurotherapeutics 14(2):385–392. doi:10.1007/s13311-017-0523-1 CrossRefPubMed

44.

Soeda A, Hara A, Kunisada T, Yoshimura S, Iwama T, Park DM (2015) The evidence of glioblastoma heterogeneity. Sci Rep 5:7979. doi:10.1038/srep07979 CrossRefPubMedPubMedCentral

45.

Teng J, Carla da Hora C, Kantar RS, Nakano I, Wakimoto H, Batchelor TT, Chiocca EA, Badr CE, Tannous BA (2017) Dissecting inherent intratumor heterogeneity in patient-derived glioblastoma culture models. Neuro Oncol 19(6):820–832. doi:10.1093/neuonc/now253 PubMed

46.

Jijiwa M, Demir H, Gupta S, Leung C, Joshi K, Orozco N, Huang T, Yildiz VO, Shibahara I, de Jesus JA, Yong WH, Mischel PS, Fernandez S, Kornblum HI, Nakano I (2011) CD44v6 regulates growth of brain tumor stem cells partially through the AKT-mediated pathway. PLoS ONE 6(9):e24217. doi:10.1371/journal.pone.0024217 CrossRefPubMedPubMedCentral

47.

Olmez I, Shen W, McDonald H, Ozpolat B (2015) Dedifferentiation of patient-derived glioblastoma multiforme cell lines results in a cancer stem cell-like state with mitogen-independent growth. J Cell Mol Med 19(6):1262–1272. doi:10.1111/jcmm.12479 CrossRefPubMedPubMedCentral

48.

Sancho-Martinez I, Nivet E, Xia Y, Hishida T, Aguirre A, Ocampo A, Ma L, Morey R, Krause MN, Zembrzycki A, Ansorge O, Vazquez-Ferrer E, Dubova I, Reddy P, Lam D, Hishida Y, Wu MZ, Esteban CR, O’Leary D, Wahl GM, Verma IM, Laurent LC, Izpisua Belmonte JC (2016) Establishment of human iPSC-based models for the study and targeting of glioma initiating cells. Nat Commun 7:10743. doi:10.1038/ncomms10743 CrossRefPubMedPubMedCentral

49.

Baker M (2012) Genome interpreter vies for place in clinical market. Nature 490(7419):157. doi:10.1038/490157a CrossRefPubMed

50.

Garralda E, Paz K, Lopez-Casas PP, Jones S, Katz A, Kann LM, Lopez-Rios F, Sarno F, Al-Shahrour F, Vasquez D, Bruckheimer E, Angiuoli SV, Calles A, Diaz LA, Velculescu VE, Valencia A, Sidransky D, Hidalgo M (2014) Integrated next-generation sequencing and avatar mouse models for personalized cancer treatment. Clin Cancer Res 20(9):2476–2484. doi:10.1158/1078-0432.CCR-13-3047 CrossRefPubMedPubMedCentral

51.

Ausman JI, Shapiro WR, Rall DP (1970) Studies on the chemotherapy of experimental brain tumors: development of an experimental model. Cancer Res 30(9):2394–2400PubMed

52.

Johanns TM, Ward JP, Miller CA, Wilson C, Kobayashi DK, Bender D, Fu Y, Alexandrov A, Mardis ER, Artyomov MN, Schreiber RD, Dunn GP (2016) Endogenous neoantigen-specific CD8 T Cells identified in two glioblastoma models using a cancer immunogenomics approach. Cancer Immunol Res 4(12):1007–1015. doi:10.1158/2326-6066.CIR-16-0156 CrossRefPubMed

53.

Gousias K, Markou M, Arzoglou V, Voulgaris S, Vartholomatos G, Kostoula A, Voulgari P, Polyzoidis K, Kyritsis AP (2010) Frequent abnormalities of the immune system in gliomas and correlation with the WHO grading system of malignancy. J Neuroimmunol 226(1–2):136–142. doi:10.1016/j.jneuroim.2010.05.027 CrossRefPubMed

54.

Fraser H (1971) Astrocytomas in an inbred mouse strain. J Pathol 103(4):266–270CrossRefPubMed

55.

Xiao A, Wu H, Pandolfi PP, Louis DN, Van Dyke T (2002) Astrocyte inactivation of the pRb pathway predisposes mice to malignant astrocytoma development that is accelerated by PTEN mutation. Cancer Cell 1(2):157–168CrossRefPubMed

56.

Reilly KM, Loisel DA, Bronson RT, McLaughlin ME, Jacks T (2000) Nf1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects. Nat Genet 26(1):109–113. doi:10.1038/79075 CrossRefPubMed

57.

Zhu H, Acquaviva J, Ramachandran P, Boskovitz A, Woolfenden S, Pfannl R, Bronson RT, Chen JW, Weissleder R, Housman DE, Charest A (2009) Oncogenic EGFR signaling cooperates with loss of tumor suppressor gene functions in gliomagenesis. Proc Natl Acad Sci USA 106(8):2712–2716. doi:10.1073/pnas.0813314106 CrossRefPubMedPubMedCentral

58.

Zeng J, See AP, Phallen J, Jackson CM, Belcaid Z, Ruzevick J, Durham N, Meyer C, Harris TJ, Albesiano E, Pradilla G, Ford E, Wong J, Hammers HJ, Mathios D, Tyler B, Brem H, Tran PT, Pardoll D, Drake CG, Lim M (2013) Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int J Radiat Oncol Biol Phys 86(2):343–349. doi:10.1016/j.ijrobp.2012.12.025 CrossRefPubMedPubMedCentral

59.

Zhang C, Burger MC, Jennewein L, Genssler S, Schonfeld K, Zeiner P, Hattingen E, Harter PN, Mittelbronn M, Tonn T, Steinbach JP, Wels WS (2016) ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma. J Natl Cancer Inst 108(5):djv375. doi:10.1093/jnci/djv375 CrossRef

60.

Parrish KE, Cen L, Murray J, Calligaris D, Kizilbash S, Mittapalli RK, Carlson BL, Schroeder MA, Sludden J, Boddy AV, Agar NY, Curtin NJ, Elmquist WF, Sarkaria JN (2015) Efficacy of PARP inhibitor rucaparib in orthotopic glioblastoma xenografts is limited by ineffective drug penetration into the central nervous system. Mol Cancer Ther 14(12):2735–2743. doi:10.1158/1535-7163.MCT-15-0553 CrossRefPubMedPubMedCentral

61.

Gupta SK, Mladek AC, Carlson BL, Boakye-Agyeman F, Bakken KK, Kizilbash SH, Schroeder MA, Reid J, Sarkaria JN (2014) Discordant in vitro and in vivo chemopotentiating effects of the PARP inhibitor veliparib in temozolomide-sensitive versus -resistant glioblastoma multiforme xenografts. Clin Cancer Res 20(14):3730–3741. doi:10.1158/1078-0432.CCR-13-3446 CrossRefPubMedPubMedCentral

62.

Garros-Regulez L, Aldaz P, Arrizabalaga O, Moncho-Amor V, Carrasco-Garcia E, Manterola L, Moreno-Cugnon L, Barrena C, Villanua J, Ruiz I, Pollard S, Lovell-Badge R, Sampron N, Garcia I, Matheu A (2016) mTOR inhibition decreases SOX2-SOX9 mediated glioma stem cell activity and temozolomide resistance. Expert Opin Ther Targets 20(4):393–405. doi:10.1517/14728222.2016.1151002 CrossRefPubMedPubMedCentral

63.

Hashizume R, Andor N, Ihara Y, Lerner R, Gan H, Chen X, Fang D, Huang X, Tom MW, Ngo V, Solomon D, Mueller S, Paris PL, Zhang Z, Petritsch C, Gupta N, Waldman TA, James CD (2014) Pharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem glioma. Nat Med 20(12):1394–1396. doi:10.1038/nm.3716 CrossRefPubMedPubMedCentral

64.

Mathieu V, De Nève N, Le Mercier M, Dewelle J, Gaussin J-F, Dehoux M, Kiss R, Lefranc F (2008) Combining bevacizumab with temozolomide increases the antitumor efficacy of temozolomide in a human glioblastoma orthotopic xenograft model. Neoplasia 10(12):1383–1392. doi:10.1593/neo.08928 CrossRefPubMedPubMedCentral

65.

Cho J, Pastorino S, Zeng Q, Xu X, Johnson W, Vandenberg S, Verhaak R, Cherniack AD, Watanabe H, Dutt A, Kwon J, Chao YS, Onofrio RC, Chiang D, Yuza Y, Kesari S, Meyerson M (2011) Glioblastoma-derived epidermal growth factor receptor carboxyl-terminal deletion mutants are transforming and are sensitive to EGFR-directed therapies. Cancer Res 71(24):7587–7596. doi:10.1158/0008-5472.CAN-11-0821 CrossRefPubMedPubMedCentral

66.

Yoshida Y, Ozawa T, Yao TW, Shen W, Brown D, Parsa AT, Raizer JJ, Cheng SY, Stegh AH, Mazar AP, Giles FJ, Sarkaria JN, Butowski N, Nicolaides T, James CD (2014) NT113, a pan-ERBB inhibitor with high brain penetrance, inhibits the growth of glioblastoma xenografts with EGFR amplification. Mol Cancer Ther 13(12):2919–2929. doi:10.1158/1535-7163.MCT-14-0306 CrossRefPubMedPubMedCentral

67.

Giannini C, Sarkaria JN, Saito A, Uhm JH, Galanis E, Carlson BL, Schroeder MA, James CD (2005) Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme. Neuro Oncol 7(2):164–176. doi:10.1215/S1152851704000821 CrossRefPubMedPubMedCentral

68.

Sarkaria JN, Carlson BL, Schroeder MA, Grogan P, Brown PD, Giannini C, Ballman KV, Kitange GJ, Guha A, Pandita A, James CD (2006) Use of an orthotopic xenograft model for assessing the effect of epidermal growth factor receptor amplification on glioblastoma radiation response. Clin Cancer Res 12(7 Pt 1):2264–2271. doi:10.1158/1078-0432.CCR-05-2510 CrossRefPubMed

69.

Pandita A, Aldape KD, Zadeh G, Guha A, James CD (2004) Contrasting in vivo and in vitro fates of glioblastoma cell subpopulations with amplified EGFR. Genes Chromosomes Cancer 39(1):29–36. doi:10.1002/gcc.10300 CrossRefPubMed

Title: Current trends in mouse models of glioblastoma
Authors: Masafumi Miyai
Hiroyuki Tomita
Akio Soeda
Hirohito Yano
Toru Iwama
Akira Hara
Publication date: 01-12-2017
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 3/2017
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-017-2626-2

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Current trends in mouse models of glioblastoma

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2017

Resident participation is not associated with postoperative adverse events, reoperation, or prolonged length of stay following craniotomy for brain tumor resection

Estimating progression-free survival in patients with glioblastoma using routinely collected data

Incidence and survival trends for medulloblastomas in the United States from 2001 to 2013

Epidemiology of glioma: clinical characteristics, symptoms, and predictors of glioma patients grade I–IV in the the Danish Neuro-Oncology Registry

Metastatic melanoma: prognostic factors and survival in patients with brain metastases

Imaging correlates for the 2016 update on WHO classification of grade II/III gliomas: implications for IDH, 1p/19q and ATRX status